Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from FTC/RPV/TDF to FTC/RPV/TAF in virologically suppressed HIV-1 infection
NL-OMON42620Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of emtricitabine, rilpivirine, tenofovir alafenamide and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoints: Proportion with HIV-1 RNA < 50 copies/mL at Week 48, Adverse events and 1 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
emtricitabinerilpivirinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON42620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42620.